Changes in serum P1NP, BAP, CTX-1, and YKL-40 following hormonal treatment for metastatic prostate carcinima are related to survival

Abstract

20002 Background: Previously it has been demonstrated that elevated P1NP, BAP, CTX-1, and YKL-40 levels at the time of diagnosis in patients with metastatic prostatic carcinoma were associated with survival. This study presents a follow-up to evaluated the prognostic value of thes biomarkers in a time-dependent analysis. Methods: Serum P1NP, BAP, CTX-1, and YKL-40 were determined in 106 patients with newly diagnozed metastatic prostatic carcinoma following start of either total androgen ablation or parenteral estrogen theraphy. Results: After 6 months of treatment significant decreases in P1NP, BAP, and YKL-40 were found. Univariate Cox analysis demonstrated that 6 month levels of P1NP, BAP, and CTX-1 were significantly associated with survival. In a multivatiate analysis using tumormarker levels at 6 months after start of treatment demonstrated that Soloway score (HR=3.9), WHO grade (HR=3.9), and P1NP (HR=2.2) all were significant predictors of survival. When using the biomarkers mentioned above as time-dependent co-variates in univariate COX regression analysis it could be shown that increasing levels og P1NP, BAP, and YKL-40 alle were significant predictors of early death. Conclusions: Serial monitoring of serum P1NP, BAP, CTX-1, and YKL-40 in patients with metastatic prostatic carcinoma during hormonal treatment provide information on prognosis. No significant financial relationships to disclose.